



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Instructions for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/531,849
				Filing Date	July 15, 2005
				First Named Inventor	Birgit C. Schultes
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AREX-P01-010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	WARD et al., 1997, Unconjugated antibodies for cancer therapy: lessons from the clinic, Cancer Treatment Reviews 23:305-319	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/28/07
--------------------	--	-----------------	----------



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/531,849
				Filing Date	July 15, 2005
				First Named Inventor	Birgit C. Schultes
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AREX-P01-010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
BB	AN	US-20020048583-A1	04-25-2002	Schultes et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CB	BAUM et al., "Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13," Hybridoma, 12(5):583-589, (1993).	
RB	CC	BLOSS et al., "OVAREX™ MAb: A Low Dose Xenotypic Antibody Approach to Ovarian Cancer Immunotherapy," Cancer Investigation, 18(1):72, (1999).	
	CD	QI et al., "Factors to Consider in Antibody-Based Immunotherapy of Cancer," Proceedings of the Annual Meeting of the American Association for Cancer Research, 41:290 (Abstract) (2000).	
	CE	SCHLEBUSCH et al., "A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer," Hybridoma, 14(2):167-174, (1995).	
	CF	SCHULTES et al., "Immunotherapy of Human Ovarian Carcinoma with OVAREX™ MAb-B43.13 in a Human PBL-SCID/BC Mouse Model," Hybridoma, 18(1):47-55, (1999).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/22/07
-----------------------	--	--------------------	----------



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/531,849
				Filing Date	April 18, 2005
				First Named Inventor	Schultes et al.
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AREX-P01-010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
✓	AA	6,086,873	07/11/2000	Sykes et al.	
✓	AB	6,241,985	06/05/2001	Madiyalakan et al.	
✓	AC	6,689,355	02/10/2004	Schultes et al.	
✓	AD	6,716,966	04/06/2004	Madiyalakan	
✓	AE	6,881,405	04/19/2005	Leveugle et al.	
✓	AF	US2001/0036457	11/01/2001	Madiyalakan et al.	
✓	AG	US2002/0022235	02/21/2002	Noujaim	
✓	AH	US2002/0048583	04/25/2002	Schultes et al.	
✓	AI	US2002/0048586	04/25/2002	Madiyalakan et al.	
✓	AJ	US2002/0132771	09/19/2002	Madiyalakan	
✓	AK	US2004/0191236	09/30/2004	Schultes et al.	
✓	AL	US2005/0048059	03/03/2005	Madiyalakan et al.	
✓	AM	US2005/063976	03/24/2005	Schultes et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
✓	BA	WO97/42973	11/20/1997	PCT WIPO	
✓	BB	WO98/33470	08/06/1998	PCT WIPO	
✓	BC	WO98/57661	12/23/1998	PCT WIPO	
✓	BD	WO99/65517	12/23/1999	PCT WIPO	
✓	BE	WO99/65523	12/23/1999	PCT WIPO	
✓	BF	WO01/12217	02/22/2001	WIPO	
✓	BG	WO01/59452	08/16/2001	WIPO	
✓	BH	WO01/85204	11/15/2001	WIPO	
✓	BI	WO01/85203	11/15/2001	WIPO	
✓	BJ	WO01/91792	12/06/2001	WIPO	
✓	BK	WO02/076384	10/03/2002	WIPO	
✓	BL	WO03/034977	05/01/2003	WIPO	
✓	BM	WO03/086041	10/23/2003	WIPO	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/28/07
-----------------------	--	--------------------	----------